RECRUITING

Evaluation of CCR2 in Patients Post Myocardial Infarction

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To determine the feasibility of 64Cu-DOTA-ECL1i, an investigational PET imaging drug, at the cellular level in the myocardium for individuals who have suffered a heart attack or who have other inflammatory heart disease.

Official Title

Preliminary Evaluation of 64Cu-DOTA-ECL1i in Patients Post-ST-Elevation Myocardial Infarction(STEMI)

Quick Facts

Study Start:2018-11-24

Study Completion:2025-11-24

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05107596

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Healthy Volunteers: 2. Age 21 to 80 years of either sex, any race 3. Capable of lying still and supine within the PET/CT and PET/MR scanner for 1 hour and follow instructions for breathing protocol during the CT portion 4. No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year 5. No known history of cardiac. pulmonary, hepatic, or renal disease or diabetes 6. No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions 7. Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol. 1. Age 21 to 80 years of either sex, any race who have suffered a STEMI within the past 6 months as well as other forms of inflammatory heart disease including sarcoidosis, myocarditis, cardiomyopathy, injected cardiovascular implantable electronic devices pacemakers/LVAD 2. Are clinically stable to undergo imaging with either PET/MR or PET/CT. 3. Capacity to give written informed consent and ability to follow study procedures 4. Pre-menopausal women must have a negative urine pregnancy test within 24 hours prior to the administration of 64-Cu-DOTA-ECL1i.	1. Currently enrolled in another study using an investigational drug 2. Angina 3. Uncontrolled heart failure 4. uncontrolled hypertension baseline hypotension below 90/50 5. Has any condition that in the opinion of the PI or designee that could increase risk to the subject 6. Is deemed likely to be unable to perform all research procedures 7. Have contraindications to PET/CT imaging like claustrophobia 8. Have contraindication to gadolinium 9. Pregnant or breastfeeding 10. Currently using recreational drubs 11. Body weight of more than 300 lbs 12. Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes 13. currently taking any prescription medications 14. Presence of an implanted device incompatible with CT or MRI scanning Inflammatory Heart Disease

Inclusion Criteria

Exclusion Criteria

1. Healthy Volunteers:
2. Age 21 to 80 years of either sex, any race
3. Capable of lying still and supine within the PET/CT and PET/MR scanner for 1 hour and follow instructions for breathing protocol during the CT portion
4. No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year
5. No known history of cardiac. pulmonary, hepatic, or renal disease or diabetes
6. No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions
7. Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol.
1. Age 21 to 80 years of either sex, any race who have suffered a STEMI within the past 6 months as well as other forms of inflammatory heart disease including sarcoidosis, myocarditis, cardiomyopathy, injected cardiovascular implantable electronic devices pacemakers/LVAD
2. Are clinically stable to undergo imaging with either PET/MR or PET/CT.
3. Capacity to give written informed consent and ability to follow study procedures
4. Pre-menopausal women must have a negative urine pregnancy test within 24 hours prior to the administration of 64-Cu-DOTA-ECL1i.

1. Currently enrolled in another study using an investigational drug
2. Angina
3. Uncontrolled heart failure
4. uncontrolled hypertension baseline hypotension below 90/50
5. Has any condition that in the opinion of the PI or designee that could increase risk to the subject
6. Is deemed likely to be unable to perform all research procedures
7. Have contraindications to PET/CT imaging like claustrophobia
8. Have contraindication to gadolinium
9. Pregnant or breastfeeding
10. Currently using recreational drubs
11. Body weight of more than 300 lbs
12. Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes
13. currently taking any prescription medications
14. Presence of an implanted device incompatible with CT or MRI scanning Inflammatory Heart Disease

Contacts and Locations

Study Contact

Kitty D Harrison, BSN, RN

CONTACT

314-747-0183

kittydharrison@wustl.edu

Study Locations (Sites)

Washington University School of Medicine

Saint Louis, Missouri, 63110

United States

Collaborators and Investigators

Sponsor: Washington University School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-11-24

Study Completion Date2025-11-24

Study Record Updates

Study Start Date2018-11-24

Study Completion Date2025-11-24

Terms related to this study

Additional Relevant MeSH Terms

Heart Diseases